Mehta Analysis: Takeda and AllianceBernstein Moves Contain A Message For Pharma
Executive Summary
Buying Shire gives Takeda the chance to exploit global tax benefits and gain other profit-promoting advantages through integrating with Shire's differently focused business. Outside of pharma, business model rationales are changing rapidly, and old certainties cannot be taken for granted. Pharma would ignore the wider revolution at its peril, and Takeda's move is a step in the right direction, argues Viren Mehta, founding partner of Mehta Partners LLC.
You may also be interested in...
Takeda To Unlock More Cash As It Preps For Shire
Takeda is aiming to free up more cash through asset disposals to help fund its planned acquisition of Shire.
Mehta Analysis: How Relevant Is Traditional Pharma In Sustainable Healthcare?
What will the healthcare industry look like over the next generation – and what role should biopharma industry managers imagine for their sustainable success? Viren Mehta, founding partner of Mehta Partners, LLC, explores the challenges for pharma companies.
Mehta Analysis: The Promise Of 2021
Next year promises a wide range of opportunities for biopharma, triggered by an all-in commitment by every company with something to combat – COVID-19. Viren Mehta of Mehta Partners LLC discusses.